The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes

被引:130
作者
Christensen, M [1 ]
Andersson, K
Dalén, P
Mirghani, RA
Muirhead, GJ
Nordmark, A
Tybring, G
Wahlberg, A
Yasar, Ü
Bertilsson, L
机构
[1] Huddinge Univ Hosp, Div Clin Pharmacol, Karolinska Inst, Dept Lab Med, S-14186 Stockholm, Sweden
[2] Pfizer Ltd, Clin Sci, Clin Pharmacokinet Pharmacodynam, Sandwich CT13 9NJ, Kent, England
关键词
D O I
10.1016/S0009-9236(03)00050-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives: Our objectives were (1) to determine whether the drugs caffeine, losartan, omeprazole, debrisoquin (INN, debrisoquine), and quinine can be given simultaneously in low doses as a cocktail for the phenotyping of cytochrome P450 (CYP) 1A2, 2C9, 2C19, 2136, and 3A4, respectively, and (2) to design an administration schedule to give as few sampling occasions as possible. Methods: Twenty-four subjects were given oral doses of 100 mg caffeine, 25 mg losartan, 20 mg omeprazole, 10 mg debrisoquin, and 250 mg quinine on separate days. After a washout period of at least 4 days, all drugs were given simultaneously except for quinine, which was given 8 hours after the other drugs. Blood and urine samples were collected to determine parent drug and metabolite concentrations for assessment of phenotyping indices. Amy difference between both single and cocktail doses was tested on a log-normal distribution. Results: The phenotypic indices of CYP1A2 (paraxanthine/caffeine in 4-hour plasma), CYP2C9 (losartan/E-3174 [metabolite of losartan] in 0- to 8-hour urine), CYP2C19 (omeprazole/5-hydroxyomeprazole in 3-hour plasma), and CYP3A4 (quinine/3-hydroxyquinine in 16-hour plasma) were not significantly changed when probe drugs were administered alone compared with together, although a tendency toward higher concentrations of losartan was seen during simultaneous administration (95% confidence interval, 0.51-1.002; P = .051). The CYP2D6 phenotypic index (debrisoquin/4-hydroxydebrisoquin in 0- to 8-hour urine) was significantly changed when drugs were given together (95% confidence interval, 0.45-0.87; P = .007), indicating an inhibition of the debrisoquin metabolism. The within-subject coefficients of variation (8%-25%) were much lower than the between-subject coefficients of variation (34%-79%). Conclusions. The administration of drugs together suggests an inhibition of debrisoquin metabolism caused by the concurrent drugs given. By separating debrisoquin from the other cocktail drugs, this method is likely to be used as a toot to phenotype the enzymes CYPIA2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 with only 2 urinary collections and 2 blood-sampling occasions.
引用
收藏
页码:517 / 528
页数:12
相关论文
共 41 条
  • [31] Assessment of CYP2D6 and CY2C19 activity in vivo in humans:: A cocktail study with dextromethorphan and chloroguanide alone and in combination
    Tennezé, L
    Verstuyft, C
    Becquemont, L
    Poirier, JM
    Wilkinson, GR
    Funck-Brentano, C
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (06) : 582 - 588
  • [32] In vitro and in vivo drug interactions involving human CYP3A
    Thummel, KE
    Wilkinson, GR
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1998, 38 : 389 - 430
  • [33] Enantioselective hydroxylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects
    Tybring, G
    Bottiger, Y
    Widen, J
    Bertilsson, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (02) : 129 - 137
  • [34] Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?
    Wanwimolruk, S
    Paine, MF
    Pusek, SN
    Watkins, PB
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (06) : 643 - 651
  • [35] NONINVASIVE TESTS OF CYP3A ENZYMES
    WATKINS, PB
    [J]. PHARMACOGENETICS, 1994, 4 (04): : 171 - 184
  • [36] The African-specific CΥP2D6*17 allele encodes an enzyme with changed substrate specificity
    Wennerholm, A
    Dandara, C
    Sayi, J
    Svensson, JO
    Abdi, YA
    Ingelman-Sundberg, M
    Bertilsson, L
    Hasler, J
    Gustafsson, LL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) : 77 - 88
  • [37] DISSOCIATION OF CO-REGULATORY CONTROL OF DEBRISOQUIN PHENFORMIN AND SPARTEINE OXIDATION IN GHANAIANS
    WOOLHOUSE, NM
    EICHELBAUM, M
    OATES, NS
    IDLE, JR
    SMITH, RL
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1985, 37 (05) : 512 - 521
  • [38] Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CΥP2C9 genotype
    Yasar, Ü
    Forslund-Bergengren, C
    Tybring, G
    Dorado, P
    Llerena, A
    Sjöqvist, F
    Eliasson, E
    Dahl, ML
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (01) : 89 - 98
  • [39] Yasar Ü, 2001, DRUG METAB DISPOS, V29, P1051
  • [40] Zhao XJ, 1996, J PHARMACOL EXP THER, V279, P1327